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Background: Reducing the incidence of anastomotic leakages would benefit both patients and health care in
general. Attempts to solve this problem have been disappointing thus far. Sylys® Surgical Sealant was developed as
an extraluminal adjunct to standard closure techniques for bowel anastomosis procedures. We describe the results
of a first-in-man study in which Sylys® Surgical Sealant is used. The aim of this study was to evaluate the safety of
Sylys® Surgical Sealant in stoma reversal procedures.
Methods: This prospective, multicenter, non-randomized, first-in-man industry initiated study was performed in two
independent hospitals in the Netherlands. The study population consisted of adults who were scheduled for an
open ileostomy reversal procedure. Exclusion critera were: patients with severe co-morbidities, patients receiving
antibiotics, immunosuppressive agents or steroids for pre-existing conditions. Follow up was conducted during
3 months after surgery at the outpatient clinic.
Results: Sixteen patients were eligible for inclusion. Twenty adverse events were recorded in 12 of the 16 treated
patients (75%). None of these events were considered to be related to Sylys® Surgical Sealant. No clinical signs of
anastomotic leakage were reported.
Conclusions: In conclusion, this first-in-man application of Sylys® Surgical Sealant as an adjunct to standard bowel
anastomosis closure techniques did not show any adverse effects in relation to the sealant in 16 patients.
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Colorectal surgery is associated with severe post-
operative complications such as peritonitis, septic shock,
multiple organ failure, and death. At least one third of the
mortality after colorectal surgery is attributed to anasto-
motic leaks [1-5]. In a recent publication by the Dutch
Surgical Colorectal Audit the incidence of anastomotic
leakage after colon and rectum resections was 8.7% [6].
Overall the reported leakage rates after colorectal surgery
varies from 3% to 23% [1-5,7]. Anastomotic leakage leads
to re-operations, admissions to intensive care units and an
increased length of hospital stay [8,9]. The cost of treating
a patient with an anastomotic leakage is on average five
times higher [10].* Correspondence: maw.stam@meandermc.nl
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unless otherwise stated.Reducing the percentage of anastomotic leakages would
benefit both patients and health care in general. Attempts
to solve this problem include, but are not limited to, staple
line reinforcements, fibrin sealants, or collagen patches.
However all with disappointing results [8,11-13].
Sylys® Surgical Sealant was developed as an extraluminal
adjunct to standard closure techniques for bowel anasto-
mosis procedures. It is a synthetic pre-polymer with
strong adherence to bowel tissue. The sealant is highly
elastic and maintains strength during the natural healing
of the anastomosis and then breaks down by hydrolysis
into non-toxic components and is resorbed by the body
within weeks.
We describe the results of a first-in-man study in
which Sylys® Surgical Sealant is used. The aim of this
study was to evaluate the safety of Sylys® Surgical Sealant
in stoma reversal procedures.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Baseline characteristics
Characteristic Mean (SD) Median (range)
Age (years) 55.2 (13.7) 58.6 (21,3-75.3)
Weight (kilogram) 78.7 (14.7) 76.5 (57.0-105.0)
Height (meter) 1.78 (0.09) 1.78 (1.64-1.97)
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A prospective, multicenter, non-randomized, first-in-man
industry initiated study was performed in two independent
hospitals in the Netherlands; Meander Medical Centre in
Amersfoort (a big teaching hospital) and Amsterdam
Medical Centre in Amsterdam (tertiary referral center).
Ethical approval was obtained by both medical ethical
committees and the Dutch Health Care Inspectorate.
Written consent was signed prior to inclusion.
Patient population
Eligible for inclusion were adults, scheduled for an open
ileostomy reversal procedure between April and May
2013. Exclusion critera were: patients with severe co-
morbidities, an ASA classification over 2, patients re-
ceiving antibiotics for pre-existing condition or infection,
steroids or immunosuppressive agents at the time of sur-
gery. Follow up was conducted at the outpatient clinic
during 3 months.
Sylys® surgical sealant
Sylys® Surgical Sealant (Cohera Medical Inc, Pittsburgh,
USA) is a polyethylene glycol (PEG)-based synthetic pre-
polymer that utilizes silane chemistry in combination
with urethane chemistry to produce a rapid curing, single-
part, moisture-cure sealant with strong adherence to bowel
tissue. Preclinical use in mice did not show any safety risks
(unpublished data).
Procedures
At least 1 hour prior to the first incision, Sylys® Surgical
Sealant was taken from frozen storage (−10°C to −30°C)
and allowed to thaw to room temperature. The surgical
procedure was consistent with techniques used for
standard open ileostomy takedown procedures. All sur-
geries were performed by experienced gastro-intestinal
surgeons. The anastomotic junction was made using ei-
ther staples, sutures or a combination of both. Upon
conclusion of constructing the anastomotic junction
Sylys® Surgical Sealant was applied circumferentially over
the staple and/or suture line using the Sylys® applicator
(Cohera Medical Inc, Pittsburgh, USA). Approximately
five minutes was allowed to pass without disruption or
manipulation of the anastomotic junction allowing Sylys®
Surgical Sealant to cure. The sealant was rinsed with
saline after 2 minutes to accelerate curing and keep the
tissues moist.
Study objectives
Primary endpoint of this study was to determine the
safety of Sylys® Surgical Sealant used during open ileos-
tomy reversal procedures. Safety was measured in terms
of complication rate and mortality during our follow-up
period. Secondary endpoints of this study were length ofhospital stay, reoperation rate, readmission rate, num-
ber/type of additional procedures due to complications
and application time and convenience. For study pur-
poses Adverse Events(AE) and Serious Adverse Events
(SAE) were reported. According to protocol all devia-
tions from the normal range had to be reported as AE,
despite recent surgery.
Statistical analysis
Numerical variables were displayed in terms of mean,
standard deviation, median and number of observations.
Categorical variables were displayed using number of
observations and percentages. Subject disposition and
safety analysis were conducted on the safety analysis set.
All other analyses were conducted on the efficacy ana-
lysis set, unless specified otherwise.
Results
Sixteen patients were eligible for inclusion. Median age
was 58.6 years (range 21.3-75.3). Median BMI 24.7 kg/m2
(range 19.6-33.4). The majority of the enrolled patients
was male (n = 13; 81.3%). [Table 1] The initial reasons
for ileostomy were surgery for: rectal cancer (n = 10),
diverticulitis (n = 3), familial adenomatous polyposis (n = 2)
and colitis (n = 1). Follow up was completed by all but one
patient.
Primary outcome: mortality and complication rate
Twenty (20) adverse events were recorded in 12 of the
16 treated patients (75%) over a three month period.
Complications were subdivided in major complications
(SAE) and minor complications (AE).
There were three major complications registered, all of
which required hospitalization: diarrhoea as a conse-
quence of chemotherapy resulting in dehydration (n = 1),
ileus (n = 1) and deep tissue wound infection (n = 1).
The latter two were interpreted as possibly device re-
lated. No clinical signs of anastomotic leakage were re-
ported. There was no mortality in this group.
Minor complications are listed in Table 2. All minor
events did not require (prolonged) hospitalization.







Diarrhea by chemotherapy 1
Deep tissue infection 1
Altered bowel habits 7






Recurrent hepatic neoplasm 1
Nausea 1
Proctitis 1
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The mean duration of the surgical procedure was 52 ±
12 minutes (n = 15). Mean time to apply the Sylys®
Surgical Sealant was 34 ± 24 seconds (n = 14). There
was no need to remove or reapply Sylys® Surgical Sealant
in any of the 16 operated patients (0%).
Hospital stay
Mean hospital stay length after the ileostomy reversal
surgery + Sylys® Surgical Sealant treatment was 3 days,
with minimum and maximum of 2 and 5 days respectively.
Reoperation and additional procedures
None of the treated patients required additional surgical
procedures or interventions.
Discussion
This safety-study did not show any adverse events re-
lated to the application of Sylys® Surgical Sealant in a
cohort of 16 patients having a ileostomy reversal pro-
cedure. Although numerous adverse events occurred,
all could be attributed to the regular postoperative
complications related to ileostomy reversal procedures.
Kaidar-Person et al. reviewed 26 studies evaluating the
complications of loop ileostomy closure. Reported rates
of small bowel obstruction range from 0% to 15% and
wound infections range from 0% to 18.3% [14]. These
findings are in line with our results.
Three serious adverse events were reported. These
were labeled serious, in line with international rules and
regulations, because of the need for hospitalization. We
considered the patient suffering from dehydration caused
by diarrhoea after chemotherapy as not related to theapplication of the device. Two SAE’s were labelled as
possibly device related. One patient suffered from an
ileus which resolved swiftly after oral laxatives. Additional
tests could not clarify the cause of the obstruction, how-
ever it was possibly related to a bowel movement disorder
caused by excessive use of piperidine derivates. The latter
patient suffered from a deep tissue infection. A causative
relationship between the two is unlikely, but cannot be
excluded.
Furthermore, none of the 16 patients showed signs of
allergic reactions towards Sylys® Surgical Sealant, indicat-
ing that the polyethylene glycol (PEG)-based synthetic
pre-polymer is well tolerated by the patients. Other
known surgical sealants have reported increased inflam-
mation and post-surgical adhesion formation. This is most
likely due to the use of cyanoacrylate products. It has been
reported that they might increase inflammatory reactions,
cause anastomotic stricture and colonic obstruction, necro-
sis and severe adhesion formation [13,15].
Applicability of the Sylys® Surgical Sealant was a major
point of interest for all participating surgeons since it
potentially leads to added procedure time and therefore
costs. Application of Sylys® Surgical Sealant over the anas-
tomotic junction required only 5 minutes of extra operat-
ing time: about 30 seconds to apply it, and 5 minutes for
the pre-polymer to adhere to the intestinal tissue.
Our study had several limitations. Firstly the number
of patients is fairly low. This was due to the nature of a
safety study. Secondly the efficacy of the sealant could
not be evaluated. To our knowledge none of the cur-
rently available coatings of intestinal anastomoses have
shown convincing results [13]. Further studies are needed
to evaluate the efficacy of Sylys® Surgical Sealant. Thirdly
Sylys® Surgical Sealant was tested in open procedures, since
the open surgical setting allowed the surgeons to easily
apply the sealant over the anastomosis. In the future, with
the rise of laparascopic procedures, this product and its ap-
plication kit will need to undergo minor modifications to
be trocar-compatible after which it needs to be tested in a
laparoscopic setting for its potential to reduce leakage of
colorectal anastomosis.
Fourth, the applicability of the sealant was tested on
an anastomosis where the sealant is simple to apply. Ap-
plication on low anterior anastomosis is expected to be
more troublesome.
Conclusion
In conclusion, this first-in-man application of Sylys®
Surgical Sealant as an adjunct to standard bowel anasto-
mosis closure techniques did not show any adverse effects
in relation to the sealant in 16 patients. Larger trials have
been scheduled to further investigate the efficacy of Sylys®
Surgical Sealant in reducing anastomotic leakage after
laparascopic colorectal surgeries.
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